Research Article
Circulating Tumor Cell Is a Clinical Indicator of Pretransplant Radiofrequency Ablation for Patients with Hepatocellular Carcinoma
Table 3
Baseline characteristics in HCC patients with/without RFA.
| | Variable | | N = 79 | | RFA (n = 18) | Non-RFA (n = 61) | | value |
| | Gender, n (%) | Male | 16 (20.3) | 58 (73.4) | 0.899 | 0.343 | | Female | 2 (2.5) | 3 (3.8) |
| | Age (years), n (%) | >50 | 8 (10.1) | 39 (49.4) | 2.191 | 0.139 | | ≤50 | 10 (12.7) | 22 (27.8) |
| | CTC count, n (%) | >1 | 8 (10.1) | 34 (43.0) | 0.712 | 0.399 | | ≤1 | 10 (12.7) | 27 (34.2) |
| | Tumor number, n (%) | >3 | 1 (1.3) | 14 (17.7) | 2.734 | 0.098 | | ≤3 | 17 (21.5) | 47 (59.5) |
| | Tumor diameter (cm), n (%) | >3 | 6 (7.6) | 9 (11.4) | 3.119 | 0.077 | | ≤3 | 12 (15.2) | 52 (65.8) |
| | PVT, n (%) | Yes | 3 (3.8) | 13 (16.5) | 0.186 | 0.667 | | No | 15 (19.0) | 48 (60.8) |
| | MVI, n (%) | Yes | 3 (3.8) | 12 (15.2) | 0.082 | 0.775 | | No | 15 (19.0) | 49 (62.0) |
| | Edmonson stage, n (%) | I-II | 11 (13.9) | 37 (46.8) | 0.001 | 0.972 | | III-IV | 7 (8.9) | 24 (30.4) |
| | Liver cirrhosis, n (%) | Yes | 17 (21.5) | 56 (71.0) | 0.138 | 0.710 | | No | 1 (1.3) | 5 (6.3) |
| | Milan criteria, n (%) | Yes | 14 (11.4) | 32 (40.5) | 3.663 | 0.056 | | No | 4 (5.0) | 29 (36.7) |
| | UCSF criteria, n (%) | Yes | 15 (18.9) | 36 (45.5) | 3.592 | 0.058 | | No | 3 (3.7) | 25 (31.6) |
| | HBsAg (+), n (%) | Yes | 14 (17.7) | 51 (64.6) | 0.324 | 0.569 | | No | 4 (5.1) | 10 (12.7) |
| | AFP (ng/ml), n (%) | >400 | 3 (3.8) | 17 (21.5) | 0.922 | 0.337 | | ≤400 | 15 (19.0) | 44 (55.7) |
| | TNM stage, n (%) | I | 1 (1.3) | 9 (11.4) | 1.723 | 0.423 | | II | 7 (8.9) | 16 (20.3) | | III-IV | 10 (12.7) | 36 (45.6) |
|
|
AFP: alpha-fetoprotein; CTC: circulating tumor cells; HBsAg: hepatitis B surface antigen; HCC: hepatocellular carcinoma; MVI: microvascular invasions; PVT: portal vein thrombosis; RFA: radiofrequency ablation; UCSF: University of California San Francisco.
|
